Daratumumab Boosts MRD Negativity, Offering New Hope for Post-Transplant Multiple Myeloma Maintenance
Table of Contents
A new analysis of data from the AURIGA study reveals that adding daratumumab to lenalidomide significantly increases rates of minimal residual disease (MRD) negativity in patients undergoing maintenance therapy following autologous stem cell transplant (ASCT) for multiple myeloma, bolstering confidence in the combination’s long-term efficacy.
The findings, discussed by a leading hematologist, demonstrate a near doubling of MRD negativity rates at both 10-5 and 10-6 thresholds with the addition of daratumumab.This is particularly impactful for patients who remain MRD positive after transplant,as the combination therapy appears to improve their chances of achieving this deeper response. “MRD negativity portends a better prognostic factor ” one expert stated, “so it increases the confidence that patients can get to these deeper responses.”
Sustained MRD Negativity: A Key Indicator of Long-Term Control
Pharmacists emphasize that sustained MRD negativity – maintaining this state for an extended period – is an even stronger predictor of long-term outcomes than achieving MRD negativity at a single time point. The AURIGA study showed a significant increase in sustained MRD negativity rates,especially at the more stringent 10-6 threshold,with the daratumumab and lenalidomide combination.
This translates to the potential for prolonged responses and a delay in disease progression. According to one pharmacy expert, patients might potentially be able to remain on therapy for longer periods, possibly up to the 36 cycles observed in the AURIGA study, if thay achieve and maintain sustained MRD negativity. However,treatment duration remains a nuanced decision,with some practices considering stopping therapy in patients with sustained MRD negativity,a strategy dependent on individual patient characteristics and disease factors.
Monitoring for Recurrence and Identifying High-Risk Patients
Effective monitoring strategies are crucial during maintenance therapy, particularly for identifying patients at risk of relapse. MRD status is typically assessed via bone marrow biopsies, though efforts are underway to develop less invasive methods using peripheral blood analysis.
The progress of MRD recurrence – a return to detectable disease after achieving negativity – serves as an early warning sign. Patients who experience this pattern are considered at higher risk of disease progression and may require a change in treatment. The AURIGA study demonstrated that adding daratumumab to lenalidomide led to lower rates of MRD recurrence, particularly in patients with standard-risk disease, with a noticeable benefit also observed in the high-risk group. “In general,” one expert noted, “the addition of daratumumab to lenalidomide may kind of slow down the recurrence of MRD.”
Why: The AURIGA study investigated the impact of adding daratumumab to lenalidomide maintenance therapy after autologous stem cell transplant (ASCT) for multiple myeloma.
Who: The study involved patients with multiple myeloma who had undergone ASCT. Experts in hematology and pharmacy contributed to the analysis and interpretation of the findings.
What: The addition of daratumumab to lenalidomide significantly increased rates of both overall and sustained MRD negativity, suggesting improved long-term disease control.
How did it end?: The AURIGA study is ongoing, but initial analysis shows that adding daratumumab to lenalidomide reduces MRD recurrence, particularly in standard-risk patients, and offers a benefit to high-risk patients. The study suggests the
